Raphael Pharmaceutical Inc.
Officers & Directors
The Chief Executive Officer provides services under a management and operations agreement with Sheffa Enterprises, Inc., receiving a monthly fee of $20,000 since January 1, 2024. Warrants previously issued to the CEO expired unexercised on December 31, 2025. The agreement was renewed and extended through December 31, 2026. The Chief Financial Officer, Guy Ofir, provides services under an operations agreement with Model Engineering & Investments SRL, receiving a monthly fee of $12,000 since January 1, 2023. He was granted 1,000,000 restricted shares and warrants, which expired unexercised on December 31, 2025. His agreement was also renewed and extended through December 31, 2026. The Chief Technology Officer, Dr. Igal Louria Hayon, provides consulting services under a service agreement, coordinating scientific collaborations and medical cannabis research. He receives 15% of net royalties from cannabis-based medical indications treating COVID-19 and was granted warrants for 350,000 shares at a $0.01 exercise price, exercised on November 20, 2025. His service agreement was renewed effective January 1, 2025, with a monthly fee of $24,000, later extended through December 31, 2027, with a monthly fee of $12,000 and reimbursement of scientific work expenses.
|
